MedTrace Logo

Single Dose CHG Pharmacokinetic Study

NCT03331263 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2023-12-15

Study results available
· View outcomes & findings →

Summary

A single 2% topical application of ReadyPrep® CHG was applied on either the abdomen (Treatment-1) or the groin (Treatment-2) whereas Treatment-3 consisted of a control treatment where the same procedure as Treatment-1 and -2 was performed, but without the topical application of ReadyPrep® CHG. The treatments were separated by a wash-out of 7 calendar days.

Conditions

  • Surgical Skin Preparation

Interventions

DRUG

Chlorhexidine Gluconate

2% CHG

Sponsors & Collaborators

  • Medline Industries

    lead INDUSTRY

Principal Investigators

  • James Carlson, Pharm D. · Algorithme Pharma USA LLC

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-07-21
Primary Completion
2017-08-06
Completion
2017-08-06
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03331263 on ClinicalTrials.gov